Request Trial
corona
Trial / Shutterstock.com
31 March 2020AmericasJonathan Tietz, Jason Mock, and Kristel Schorr

COVID-19: patent procurement and licensing

Public health officials have said that we can expect the coronavirus pandemic to last for months—and the underlying virus will likely be with us for the long term. Meanwhile, the response to the COVID-19 pandemic has included a flurry of innovation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
5 ways the USPTO director is changing US innovation
24 December 2025   John Squires has rewired the country’s patents system since becoming USPTO director—but which changes are most impactful? Sarah Speight explores.
Americas
Mirum targets generics in quartet of suits over liver treatment
22 December 2025   Biopharma company and two others have taken action against numerous defendants over proposed generic versions of Livmarli, Mirum’s core revenue driver.
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025   The proponents of a petition denied by the Supreme Court said it addressed a conflict that was significant “not just for the pharmaceutical industry, but for all stakeholders in our patent system”.


Editor's picks

SCOTUS shuts the door on Entresto ‘after-arising technology’ review
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025

Editor's picks

Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025

More features

Mental health in IP: ‘We have a clear picture of the problem’
From Edwards to Insulet: Three key medical device cases of 2025
5 ways the USPTO director is changing US innovation
EU unveils sweeping pharma, biotech, and medical device reforms
Mirum targets generics in quartet of suits over liver treatment
Hogan Lovells and Cadwalader strike historic deal to create $3.6bn firm
WATCH: Enabling success — overcoming §112 in the new era of life sciences patents
Edwards v Meril: 3 insights from the UPC Court of Appeal’s decision